首页> 外文期刊>Journal of Inorganic Biochemistry: An Interdisciplinary Journal >Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs
【24h】

Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs

机译:谷胱甘肽诱导对阳离子双核铂抗癌药的细胞耐药性

获取原文
获取原文并翻译 | 示例
           

摘要

The sulfur-containing tripeptide glutathione (GSH) is one of the most abundant molecules in cells. Elevated levels of GSH render some types of cancer cells resistant against well-known platinum anti-cancer drugs such as cisplatin and carboplatin. Platinum complexes are often very reactive towards the cysteine residue of GSH, which detoxifies these compounds by a rapid binding mechanism. Clearly, this resistance mechanism poses a severe obstacle to any new platinum drugs designed to overcome cisplatin resistance. In the present study the cytotoxicity of dinuclear platinum compounds of the 1, 1 /t,t type, as developed by Farrell, is determined in human ovarium A2780 cells and in the cisplatin-resistant cell line A2780cisR, which possesses elevated levels of GSH. Further, the effect of depletion of GSH levels by L-buthionine-S,R-sulfoxiniine (L-BSO) in A2780cisR was investigated. The experiments show that detoxification by GSH is an effective resistance mechanism against dinuclear platinum compounds. However, the dinuclear complexes are less sensitive towards detoxification compared to cisplatin. This is probably because of the rapid binding of dinuclear cationic complexes to DNA. Compared to cisplatin, the rapid binding to DNA reduces the time during which the drug molecules are exposed to GSH in the cytosol. The reaction of a representative dinuclear compound with glutathione (pH 7, 37 degreesC) was studied in detail by Pt-195 NMR. The dinuclear complex BBR3005 ([trans-PtCl2(NH3)(2)(mu-H2N(CH2)(6)NH2)](2+), abbreviated as 1,1/t,t n=6), follows different pathways in the reaction with GSH, depending on the molar ratio of the reactants. When reacted in stoichometric amounts (1:1), first a chloride on each platinum is replaced by a sulfur, forming a PtN3S product at -2977 ppm. After 2-3 h, this intermediate reacts further to form a sulfur-bridged N3Pt-S-PtN3 species as the main product at -2811 ppm. When BBR3005 is reacted with GSH in a ratio of 1:4, the sulfur-bridged species is not observed. Instead, the final product is trans-Pt(GS)(2)(NH3)(2) (at -3215 ppm); the same product appears if GSH is reacted with trans-PtCl2(NH3)(2). Apparently, GSH first replaces the chlorides and subsequently degrades the dinuclear compound by replacement of the diaminealkyl linker.
机译:含硫三肽谷胱甘肽(GSH)是细胞中最丰富的分子之一。谷胱甘肽水平升高会导致某些类型的癌细胞对众所周知的铂类抗癌药物(例如顺铂和卡铂)产生耐药性。铂络合物通常对GSH的半胱氨酸残基具有很高的反应性,从而通过快速结合机制使这些化合物解毒。显然,这种耐药机制对任何旨在克服顺铂耐药性的新铂药物构成了严重的障碍。在本研究中,由Farrell开发的1,1 / t,t型双核铂化合物的细胞毒性是在人卵巢A2780细胞和顺铂耐药细胞系A2780cisR(其GSH含量升高)中确定的。此外,研究了在A2780cisR中L-蛋氨酸-S,R-磺胺基辛胺(L-BSO)消耗GSH的作用。实验表明,谷胱甘肽的解毒是对双核铂化合物的有效抵抗机制。但是,与顺铂相比,双核复合物对排毒的敏感性较低。这可能是由于双核阳离子复合物与DNA的快速结合。与顺铂相比,与DNA的快速结合减少了药物分子在细胞质中暴露于GSH的时间。通过Pt-195 NMR详细研究了代表性的双核化合物与谷胱甘肽的反应(pH 7、37℃)。双核复合物BBR3005([trans-PtCl2(NH3)(2)(mu-H2N(CH2)(6)NH2)](2+),缩写为1,1 / t,tn = 6),遵循不同的途径与GSH的反应,取决于反应物的摩尔比。当以化学计量的量(1:1)反应时,首先将每个铂上的氯化物替换为硫,形成-2977 ppm的PtN3S产物。 2-3小时后,该中间体进一步反应形成硫桥连的N3Pt-S-PtN3物质,其主要产物为-2811 ppm。当BBR3005与GSH以1:4的比例反应时,未观察到硫桥联物质。相反,最终产物是反式Pt(GS)(2)(NH3)(2)(在-3215 ppm处);如果GSH与反式PtCl2(NH3)(2)反应,则会出现相同的产物。显然,GSH首先取代了氯化物,随后通过取代了二胺烷基连接基使双核化合物降解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号